The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Will CAR T-cell therapy change the treatment landscape for MCL?

During the 3rd European CAR T-cell Meeting, the Lymphoma Hub spoke to Marion Subklewe, Ludwig-Maximilians-Universität München, Munich, DE. We asked, Will CAR T-cell therapy change the treatment landscape for MCL?

Will CAR T-cell therapy change the treatment landscape for MCL?

The current standard of care for young, fit patients with mantle cell lymphoma (MCL) is chemotherapy-based induction regimens followed by autologous stem cell transplantation (auto-SCT) for consolidation. In patients with relapsed/refractory (R/R) MCL, second-line treatment involves Bruton's tyrosine kinase inhibitors, such as ibrutinib/acalabrutinib.

There is a subset of R/R patients with high-risk disease that has an overall survival of less than 4 years, and this group is the target for testing treatment with CAR T-cells. Marion Subklewe discusses the results of the ZUMA-2 trial evaluating anti-CD19 CAR T-cells in this subset of patients with R/R MCL.

Share: